A study led by Flinders University and Flinders Medical Center analyzed data from 1,691 Australians with bowel cancer that had spread only to the liver. ^[1] Anaplastic thyroid carcinoma (ATC) is characterized by a heterogeneous mutational landscape with recurrent alterations in BRAF, RAS, and TP53 genes. ^[2] Professor Savio (George) Barreto, a consultant with the HPB and Liver Transplant Unit at Flinders Medical Center, stated that younger patients differed from older patients in tumor biology, disease characteristics, and survival outcomes. ^[3] The study found that patients diagnosed with bowel cancer at age 50 or younger were more likely to be women and have tumors on the left side of the bowel. ^[4] Younger patients in the study were more likely to have tumors carrying specific genetic mutations compared to older patients. ^[5] A nonrandomized clinical trial evaluated anti-programmed death ligand 1 plus targeted therapy in patients with anaplastic thyroid carcinoma. ^[6] Dabrafenib and trametinib treatment was studied in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. ^[7] Whole-exome sequencing revealed less frequent mutations in PI3K-pathway, cell-cycle, and DNA mismatch-repair genes that could represent therapeutic vulnerabilities. ^[8]